Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.55 |
| ▸ | DUT | P33316 | 11/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6864606 | 0.89 | DUT (0.57) | PKMCRBNDUTL3MBTL1 | |
| SCHEMBL4348697 | 0.87 | L3MBTL1 (0.59) | PKMCRBNDUTL3MBTL1 | |
| SCHEMBL7837324 | 0.87 | DUT (0.56) | PKMCRBNDUT | |
| SCHEMBL17372138 | 0.85 | DUT (0.55) | PKMDUT | |
| SCHEMBL1923335 | 0.83 | PKM (0.61) | PKMCRBNDUTL3MBTL1 | |
| SCHEMBL14861415 | 0.82 | L3MBTL1 (0.54) | PKMCRBNDUTL3MBTL1 | |
| SCHEMBL26915664 | 0.81 | L3MBTL1 (0.58) | PKMCRBNDUTL3MBTL1 | |
| SCHEMBL41240 | 0.81 | PKM (0.42) | PKMCRBNDUTL3MBTL1 | |
| SCHEMBL24066362 | 0.80 | PKM (0.50) | PKMCRBNDUTL3MBTL1 | |
| SCHEMBL16632410 | 0.80 | L3MBTL1 (0.53) | PKMCRBNDUTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| EP-0252043-A1 | Method for the preparation of 3-n-propyl-xanthine | Aktiebolaget Draco (SE) | 1988-01-07 | — | — | EP | claimed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-2872485-B1 | ASYMMETRIC AUXILIARY GROUP | WAVE LIFE SCIENCES LTD (SG) | 2020-12-16 | — | — | EP | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10544105-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-01-28 | — | — | US | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| CN-1436082-A | 3 '-or 2' -hydroxymethyl substituted nucleoside derivatives for the treatment of hepatitis virus infections | PHARMASSET LTD (BB) | 2003-08-13 | — | — | CN | disclosed |
| EP-1284741-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | Pharmasset, Ltd. (BB) | 2003-02-26 | — | — | EP | disclosed |
| CN-1347418-A | Novel nucleosides and oligonucleotide analogues | SANKYO CO (JP) | 2002-05-01 | — | — | CN | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | disclosed |
| EP-0252043-A1 | Method for the preparation of 3-n-propyl-xanthine | Aktiebolaget Draco (SE) | 1988-01-07 | — | — | EP | disclosed |
| EP-0252043-A1 | Method for the preparation of 3-n-propyl-xanthine | Aktiebolaget Draco (SE) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | PKM 3383/4885CRBN 1/4885DUT 4627/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | PKM 3383/4885CRBN 1/4885DUT 4627/4885 |
| US-10544105-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | DPYD, DUT, TYMP | PKM 3340/4885CRBN 3608/4885DUT 2/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PKM 2875/4885CRBN 2596/4885DUT 116/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PKM 2875/4885CRBN 2596/4885DUT 116/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PKM 2875/4885CRBN 2596/4885DUT 116/4885 |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | NSUN2, RNGTT, NSUN3 | PKM 2875/4885CRBN 2596/4885DUT 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.